TEVA(TEVA) - 2023 Q3 - Earnings Call Presentation

Potential to be first long-acting olanzapine with a favorable safety profile 官 H2 2026 - Phase III results $2.5bn Anti-TL1A (TEV-'574) H2 2024 – Phase II interim $28bn 14 | Target Updates Access programs launched (of 8 - 2025 target) cumulative regulatory submissions* (51% of 2025 target) reduction in scope 1 and 2 greenhouse gas emissions (52% of 2030 target) of employees trained on compliance policies** Winner: Best Company for Sustainability Reporting Finalist: Best Company for Social Responsibility dose ...